HMGB1 and colorectal carcinoma: It has been shown that platelets in CRC patients stimulate neutrophils to produce NETs, which can be inhibited by depletion of HMGB1, and that the level of NETs in the blood of CRC patients increases in parallel with cancer progression, leading to a shortened clotting time and a significant increase in thrombo-antithrombotic complexes and fibrin fibrils, compared to healthy subjects.